@article{JTD25499,
author = {Rossana Berardi},
title = {KEYNOTE-024: goodbye to chemotherapy?},
journal = {Journal of Thoracic Disease},
volume = {11},
number = {Suppl 3},
year = {2018},
keywords = {},
abstract = {In the last 2 years the therapeutic landscape of non-small cell lung cancer (NSCLC) has seen a rapid shift with the introduction of immunotherapy into treatment strategy. Studies have demonstrated superior overall survival (OS) for monoclonal antibody therapy, directed against either the PD-1 receptor [nivolumab (1,2) and pembrolizumab (3)] or its ligand [PD-L1, atezolizumab (4,5)], when compared with docetaxel chemotherapy.},
issn = {2077-6624}, url = {https://jtd.amegroups.org/article/view/25499}
}